Mail

UK markets closed

NIKKEI 225
37,552.16
+113.55(+0.30%)
HANG SENG
16,828.93
+317.24(+1.92%)
CRUDE OIL
83.32
+1.42(+1.73%)
GOLD FUTURES
2,341.10
-5.30(-0.23%)
DOW
38,510.56
+270.58(+0.71%)
Bitcoin GBP
53,584.86
+167.57(+0.31%)

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Roche Holding AG (0QOK.IL)

IOB - IOB Delayed price. Currency in CHF

Add to watchlist

227.25

+0.20

(+0.09%)

At close: 06:09PM BST

Full screen

Previous close	227.05
Open	227.50
Bid	221.60 x N/A
Ask	232.90 x N/A
Day's range	224.30 - 232.00
52-week range	216.50 - 298.40
Volume	553,472
Avg. volume	963,875

Market cap	192.837B
Beta (5Y monthly)	0.18
PE ratio (TTM)	17.48
EPS (TTM)	N/A
Earnings date	N/A
Forward dividend & yield	9.50 (3.99%)
Ex-dividend date	16 Mar 2023
1y target est	N/A

All

News

Press releases

Globe Newswire
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF
Business Wire
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
SOUTH SAN FRANCISCO, Calif., April 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people wi
Business Wire
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
SOUTH SAN FRANCISCO, Calif., April 17, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from the Phase III OCARINA II study (S31.006) of Ocrevus® (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigatio

NIKKEI 22537,552.16+113.55(+0.30%)

HANG SENG16,828.93+317.24(+1.92%)

CRUDE OIL83.32+1.42(+1.73%)

GOLD FUTURES2,341.10-5.30(-0.23%)

DOW38,510.56+270.58(+0.71%)

Bitcoin GBP53,584.86+167.57(+0.31%)

What is the true cost of the UK state pension?

Roche Holding AG (0QOK.IL)

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

NIKKEI 225
37,552.16
+113.55(+0.30%)

HANG SENG
16,828.93
+317.24(+1.92%)

CRUDE OIL
83.32
+1.42(+1.73%)

GOLD FUTURES
2,341.10
-5.30(-0.23%)

DOW
38,510.56
+270.58(+0.71%)

Bitcoin GBP
53,584.86
+167.57(+0.31%)